Seelos Therapeutics Inc (SEEL)

[zmanindc]

Not good news and testosterone therapies are out of favor with the FDA.

This is now their third try at an acquisition and brings with it more dilution, debt and now a swift end to this investment. If the drug fails phase III, or the FDA says no we are done. I thought Rayva was first or did they lie about that? If you have not been following the news, there is a growing concern amongst therapists that testosterone therapy increases the risk of heart disease. It will be interesting to see if any new T treatments are approved. Already RPRX was hit with a setback.

This management team can't focus.